This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.


Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Accession Number

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Not Available
External IDs
CAS number


Not Available
Not Available
Mechanism of action
Not Available
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Not Available
Route of elimination
Not Available
Half life
Not Available
Not Available
Not Available
Affected organisms
Not Available
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Camrelizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Camrelizumab.
AbrilumabThe risk or severity of adverse effects can be increased when Camrelizumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Camrelizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Camrelizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Camrelizumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Camrelizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Camrelizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Camrelizumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


General References
Not Available
External Links

Clinical Trials

Clinical Trials
1Active Not RecruitingOtherLung Cancers1
1Active Not RecruitingTreatmentBreast Cancer / Gastrointestinal Cancers1
1Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
1CompletedTreatmentNeoplasms / Solid Tumors and Hematologic Malignancy1
1Enrolling by InvitationTreatmentNeoplasms1
1Not Yet RecruitingTreatmentAdvanced Solid Tumors1
1Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Not Yet RecruitingTreatmentMetastatic Cancers / Neoplasms Malignant / Tumors, Solid1
1RecruitingTreatmentAdvanced Gastric Cancer1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentTumors, Solid1
1, 2Not Yet RecruitingTreatmentAdvanced Malignant Solid Tumor1
1, 2Not Yet RecruitingTreatmentCRC / HCC / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentChronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms / Respiratory Tract Diseases / Thoracic Neoplasms1
1, 2Not Yet RecruitingTreatmentHepatic Metastasis of Colorectal Cancer1
1, 2Not Yet RecruitingTreatmentLung Cancers1
1, 2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentAdvanced Gastric Cancer1
1, 2RecruitingTreatmentBiliary Tract Cancer1
1, 2RecruitingTreatmentEffect of Drugs / Pediatric Cancer / Progression1
1, 2RecruitingTreatmentHepatocellular,Carcinoma / Malignant Neoplasm of Stomach1
1, 2RecruitingTreatmentHepatocellular,Carcinoma / Transplantation, Liver1
1, 2RecruitingTreatmentImmunotherapy / Radiotherapy / Rectal Carcinoma1
1, 2RecruitingTreatmentPrimary mediastinal large B-cell lymphomas1
1, 2RecruitingTreatmentRecurrent Colorectal Cancer1
1, 2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentBreast Cancer1
2Active Not RecruitingTreatmentHepatocellular Carcinoma Non-resectable1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentClinical Benefit Rate / Overall Survival / Progression-free Survival / Therapeutic Agent Toxicity1
2Enrolling by InvitationTreatmentAdvanced Gastric Cancer / EBV1
2Not Yet RecruitingOtherNSCLC Stage IV1
2Not Yet RecruitingTreatmentChemotherapy Effect / KRAS Gene Mutation / NSCLC Stage IV / PD-1 Antibody1
2Not Yet RecruitingTreatmentEsophageal Cancers1
2Not Yet RecruitingTreatmentEsophageal Squamous Cell Carcinoma (ESCC)2
2Not Yet RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Not Yet RecruitingTreatmentGastric Adenocarcinoma1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma2
2Not Yet RecruitingTreatmentCancer treatment / Hypopharyngeal Carcinoma / Immunotherapy1
2Not Yet RecruitingTreatmentLocally Advanced Esophageal Squamous Cell Carcinoma1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Stage II / PD-1 Antibody1
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach4
2Not Yet RecruitingTreatmentNK/T-cell Lymphoma1
2Not Yet RecruitingTreatmentNasopharyngeal Carcinoma1
2Not Yet RecruitingTreatmentNeoplasms, Lung1
2Not Yet RecruitingTreatmentRecurrent, Platinum-resistant Ovarian Cancer1
2Not Yet RecruitingTreatmentSmall Cell Lung Cancer Extensive Stage1
2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentAFP / Malignant Neoplasm of Stomach1
2RecruitingTreatmentAdvanced Biliary Tract Carcinoma / Advanced Primary Liver Cancer1
2RecruitingTreatmentAdvanced Gastric Cancer1
2RecruitingTreatmentAdvanced Non Small Cell Lung Cancer / Soft Tissue Sarcoma (STS) / Uterine Malignancies1
2RecruitingTreatmentAnti-PD-1 Antibody / Cancer treatment / Immunotherapy / Persistent Advanced Cervical Carcinoma / Recurrent Cervical Carcinoma1
2RecruitingTreatmentApatinib / Cancer, Advanced / Mucosal Melanoma / SHR-12101
2RecruitingTreatmentBCLC Stage B Hepatocellular Carcinoma / BCLC Stage C Hepatocellular Carcinoma1
2RecruitingTreatmentBiliary Tract Cancer / Cholangiocarcinomas1
2RecruitingTreatmentC-staged Hepatocellular Carcinoma in BCLC Classification1
2RecruitingTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms, Lung / Respiratory Tract Diseases / Respiratory tract neoplasms NEC1
2RecruitingTreatmentCervical Cancers / Endometrial Cancer / Recurrent Ovarian Cancer / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
2RecruitingTreatmentClassical Hodgkin's Lymphoma1
2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Metastic Renal Cell Carcinoma / Renal Cell Adenocarcinoma / Second-line Treatment1
2RecruitingTreatmentEsophageal Diseases / Gastrointestinal Diseases / Neoplasms, Esophageal / Neoplasms, Gastrointestinal1
2RecruitingTreatmentEsophageal Diseases / Neoplasms, Esophageal1
2RecruitingTreatmentEsophageal Squamous Cell Carcinoma (ESCC)1
2RecruitingTreatmentEsophageal Squamous Cell Carcinoma (ESCC) / Immunotherapy1
2RecruitingTreatmentGastroesophageal Cancer (GC) / Malignant Neoplasm of Stomach1
2RecruitingTreatmentGestational Trophoblastic Disease1
2RecruitingTreatmentHodgkin Lymphoma, Adult1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small-Cell Lung Cancer / Tumors Metastatic to Brain1
2RecruitingTreatmentLymphoma, Hodgkins3
2RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
2RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2RecruitingTreatmentRecurrent Cervical Carcinoma / Recurrent, IV-B Cervical cancer1
2TerminatedTreatmentMetastatic Colorectal Cancer (MCRC)1
2, 3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma1
2, 3RecruitingTreatmentGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma1
3CompletedTreatmentEsophageal Carcinoma1
3Not Yet RecruitingTreatmentChemotherapy Effect / Lung Cancer Squamous Cell / Lung carcinoma cell type unspecified stage IV / PD-1 Antibody1
3Not Yet RecruitingTreatmentGastroesophageal Cancer (GC) / Malignant Neoplasm of Stomach1
3Not Yet RecruitingTreatmentPD-L1 Positive Non-small Cell Lung Cancer1
3RecruitingTreatmentAdvanced Esophageal Cancers1
3RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
3RecruitingTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms by Site / Neoplasms, Lung / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms1
3RecruitingTreatmentLocally Advanced or Metastatic and Unresectable HCC1
3RecruitingTreatmentNasopharyngeal Carcinoma1
3RecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableCompletedTreatmentEsophageal Cancers1
Not AvailableNot Yet RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
Not AvailableRecruitingPreventionHepatocellular,Carcinoma1
Not AvailableRecruitingTreatmentEsophageal Cancers1
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma1
Not AvailableRecruitingTreatmentPancreatic Cancer Stage IV1


Not Available
Not Available
Dosage forms
Not Available
Not Available
Not Available


Not Available
Experimental Properties
Not Available


Not classified

Drug created on May 20, 2019 08:26 / Updated on February 02, 2020 03:16